Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an in vivo Model of Invasive Pulmonary Aspergillosis.

Zhao M, Lepak AJ, Marchillo K, Vanhecker J, Sanchez H, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02372-18. doi: 10.1128/AAC.02372-18. [Epub ahead of print]

PMID:
30670426
2.

In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01067-18. doi: 10.1128/AAC.01067-18. Print 2018 Sep.

PMID:
29987156
3.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

4.

In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00250-17. doi: 10.1128/AAC.00250-17. Print 2017 Jul.

5.

In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02368-16. doi: 10.1128/AAC.02368-16. Print 2017 May.

6.

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.

Lepak A, Marchillo K, VanHecker J, Azie N, Andes D.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):674-7. doi: 10.1128/AAC.02124-15. Print 2016 Jan.

7.

Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.

Lepak A, Marchillo K, VanHecker J, Andes D.

Antimicrob Agents Chemother. 2015 Dec;59(12):7833-6. doi: 10.1128/AAC.01717-15. Epub 2015 Sep 21.

8.

In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.

Lepak AJ, Parhi A, Madison M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2015 Oct;59(10):6568-74. doi: 10.1128/AAC.01464-15. Epub 2015 Aug 10.

9.

Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6284-9. doi: 10.1128/AAC.01355-13. Epub 2013 Oct 7.

10.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.

11.

Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47. doi: 10.1128/AAC.00833-13. Epub 2013 Aug 19.

12.

Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Jan;57(1):579-85. doi: 10.1128/AAC.01279-12. Epub 2012 Nov 12.

Supplemental Content

Loading ...
Support Center